NA
CAI

NewEdge Advisors’s Caris Life Sciences CAI Stock Holding History

NewEdge Advisors’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.56K Hold
200
– – ﹤0.01% 3807
2026
Q1 		$3.58K Hold
200
– – ﹤0.01% 3674
2025
Q4 		$5.4K Hold
200
– – ﹤0.01% 3658
2025
Q3 		$6.05K Hold
200
– – ﹤0.01% 3477
2025
Q2 		$5.34K Buy
+200
New +$5.39K ﹤0.01% 3391

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

NewEdge Advisors's CAI Position: Q2 2026 in Review

NewEdge Advisors held its Caris Life Sciences (CAI) position steady in Q2 2026 at 200 shares worth $3.56K. The position accounts for ﹤0.01% of the portfolio, ranked #3807.

NewEdge Advisors first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.05K in Q3 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • NewEdge Advisors held 200 shares of Caris Life Sciences worth $3.56K as of Q2 2026.
  • NewEdge Advisors left its Caris Life Sciences share count unchanged in Q2 2026.
  • Caris Life Sciences made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3807 holding.
  • NewEdge Advisors first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • NewEdge Advisors's Caris Life Sciences position peaked at $6.05K in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.